國立虎尾科技大學 |

New approaches to drug discovery

Record Type:	Language materials, printed : Monograph/item
Title/Author:	New approaches to drug discovery/ edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
other author:	Nielsch, Ulrich.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	viii, 341 p. :ill., digital ; : 24 cm.;
Contained By:	Springer eBooks
Subject:	Drug development. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-28914-4
ISBN:	9783319289144

New approaches to drug discovery
New approaches to drug discovery[electronic resource] /edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch. - Cham :Springer International Publishing :2016. - viii, 341 p. :ill., digital ;24 cm. - Handbook of experimental pharmacology,v.2320171-2004 ;. - Handbook of experimental pharmacology ;v.212..

Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.

This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.

ISBN: 9783319289144

Standard No.: 10.1007/978-3-319-28914-4doiSubjects--Topical Terms:

581824
Drug development.

LC Class. No.: RM301.25

Dewey Class. No.: 615.1072

New approaches to drug discovery
LDR:02742nam a2200325 a 4500 001 862839
003 DE-He213
005 20160909092617.0
006 m d
007 cr nn 008maaau
008 170720s2016 gw s 0 eng d
020 $a 9783319289144 $q (electronic bk.)
020 $a 9783319289120 $q (paper)
024 7 $a 10.1007/978-3-319-28914-4 $2 doi
035 $a 978-3-319-28914-4
040 $a GP $c GP
041 0 $a eng
050 4 $a RM301.25
072 7 $a MMG $2 bicssc
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 615.1072 $2 23
090 $a RM301.25 $b .N532 2016
245 0 0 $a New approaches to drug discovery $h [electronic resource] / $c edited by Ulrich Nielsch, Ulrike Fuhrmann, Stefan Jaroch.
260 $a Cham : $c 2016. $b Springer International Publishing : $b Imprint: Springer,
300 $a viii, 341 p. : $b ill., digital ; $c 24 cm.
490 1 $a Handbook of experimental pharmacology, $x 0171-2004 ; $v v.232
505 0 $a Preface -- Part 1. Historical View -- Drug discovery in the past and today.Part 2. Target Discovery -- Emerging target families: intractable targets. In vivo target validation especially for biological targets. HR RNAi/High Content analysis -- Part 3. Lead generation and Optimization -- Sources for leads: natural products, libraries. Screening: assays, readout, technology. Impact of structural biology, fragment based screening/Virtual screening. Predictive in silico tools of compound properties. High throughput synthesis. New compound classes: Protein-Protein Interaction. Sources for biological leads/Screening of biologicals -- Part 4. Test systems for Efficacy and Safety -- In vitro / Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impact of biomarkers/personalized medicine. Simulating in vivo drug effects.
520 $a This volume gives an overview of state of the art technologies and future developments in the field of preclinical pharmaceutical research. A balanced mix of experts from academia and industry give insight in selected new developments in the drug discovery pathway. The topics cover the different parts of the drug discovery process, starting with new developments in the target identification and validation area. The lead generation part as a next step focuses on the requirements and technologies to identify new small molecules as lead compounds for further optimization; in a second section the technologies to identify biologics as leads are addressed. The final part focuses on the pharmacological models and technologies to characterize new compounds and the impact of biomarkers to facilitate the transfer of drug candidates into the development phase.
650 0 $a Drug development. $3 581824
650 0 $a Pharmacology. $3 583819
650 0 $a Pharmacy $x Research. $3 1028313
650 0 $a Clinical biochemistry. $3 591508
650 1 4 $a Biomedicine. $3 593880
650 2 4 $a Pharmacology/Toxicology. $3 593882
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
650 2 4 $a Medical Biochemistry. $3 668897
650 2 4 $a Metabolomics. $3 882386
700 1 $a Nielsch, Ulrich. $3 1106485
700 1 $a Fuhrmann, Ulrike. $3 1106486
700 1 $a Jaroch, Stefan. $3 1106487
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer eBooks
830 0 $a Handbook of experimental pharmacology ; $v v.212. $3 882814
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-28914-4
950 $a Biomedical and Life Sciences (Springer-11642)